^
Association details:
Biomarker:TFE3 fusion
Cancer:Sarcoma
Drug:pazopanib (Multi-tyrosine kinase inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Pazopanib for Metastatic Alveolar Soft Part Sarcoma

Excerpt:
...- Histologically confirmed diagnosis of alveolar soft part sarcoma harboring TFE3 fusion at stage IV or at relapse...
Trial ID:
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

The utility of integrative genomic profiling in sarcoma diagnosis and treatment.

Published date:
05/16/2018
Excerpt:
A sixteen year old patient, who was diagnosed by NGS as alveolar soft part sarcoma featured by TFE3 fusion with primary lesion on left thigh and distal brain metastasis, achieved partial response after three months of pazopanib treatment.